Rebecca Griffith-Eskew

Mrs. Griffith-Eskew has more than 25 years of clinical development and operations experience in oncology drug development, phases 1 - 4. Mrs. Griffith- Eskew has been a part of multiple successful NDA and BLA submissions, including Ofatumumab, Temozolomide, the early Venetoclax trials in AML, and label expansions for Avelumab. During her career, Rebecca has managed, monitored, and overseen on an executive level multiple solid tumors and hematological malignancy trials and oncology portfolios. Mrs. Griffith-Eskew was the head of clinical operations at Immatics, a small biotech company focused on T-Cell therapy, as well as an Executive Director/ Franchise Area Lead overseeing a portfolio of oncology trials at Worldwide Clinical Trials.

Mrs. Griffith-Eskew earned a B.S. in Zoology from the University of Oklahoma and is a candidate for an M.S. in Sport Psychology from Walden University.